title: [Perceptions of benign prostatic hyperplasia according to the perspective of patients and general practitioners - the Trophée study].
abstract: OBJECTIVE
  To compare the perception of benign prostatic hypertrophy (BPH) between patients and general practitioners (GPs) in terms of severity and evolution of symptoms and medication adherence.
  
  
  METHODS
  A cross-sectional observational study was performed in France in a sample of GPs who included patients for whom a BPH treatment was prescribed. Data were collected on patient and GP characteristics, diagnosis, BPH management, severity and evolution of symptoms and medication adherence.
  
  
  RESULTS
  One thousand and ninety-eight patients were recruited by 247 GPs. In 87.4% of cases, diagnosis was performed by GPs. Among them, 82.7% of patients were treated by monotherapy. The choice of a treatment was mainly based on treatment efficacy and the patient's opinion was taken into account by 5% of GPs. The patient's evaluation of symptoms severity was consistent with the GP's in 53.9% of cases. A worsening of symptoms was reported significantly more frequently by patients (18.5%) than by GPs (8.8%). Among 94 patients who reported poor adherence, GPs estimated that the level of medication adherence was good for 72 of these (77%).
  
  
  CONCLUSIONS
  There was discordance between the evaluation made by GPs and by patients on the perception of BPH symptoms and medication adherence. The patient's opinion was rarely taken into account in the therapeutic decision, reflecting a lack of shared medical decision-making, which would be helpful for the physician in order to optimize BPH management.
authors.affiliation: Médecine générale, immeuble La Source, rue René-Cassin, 73410 Albens, France. f.lacoin@irmg.fr
authors.forename: F
authors.initials: F
authors.lastname: Lacoin
authors.forename: R-O
authors.initials: RO
authors.lastname: Fourcade
authors.forename: M
authors.initials: M
authors.lastname: Rouprêt
authors.forename: A
authors.initials: A
authors.lastname: Slama
authors.forename: C
authors.initials: C
authors.lastname: Le Fur
authors.forename: E
authors.initials: E
authors.lastname: Michel
authors.forename: A
authors.initials: A
authors.lastname: Sitbon
authors.forename: F-E
authors.initials: FE
authors.lastname: Cotté
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D001294:Attitude to Health; D003430:Cross-Sectional Studies; D005602:France; D058005:General Practitioners / Q000523:psychology*; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D055118:Medication Adherence / Q000523:psychology*; D008875:Middle Aged; D010353:Patient Education as Topic / Q000379:methods; D010361:Patients / Q000523:psychology*; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology*; D011788:Quality of Life; D012307:Risk Factors; D012494:Sampling Studies; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000317:Adrenergic alpha-Antagonists